The Role of Cytokines in Cancer Cachexia
- 1 November 1992
- journal article
- review article
- Published by Wiley in Journal of Parenteral and Enteral Nutrition
- Vol. 16 (6S) , 43S-49S
- https://doi.org/10.1177/014860719201600602
Abstract
There is, at present, considerable interest in the possible role for the proinflammatory cytokines, tumor necrosis factor-α, interleukin-1, interleukin-6, and interferon-γ in the pathogenesis of cancer cachexia. Indirect evidence for such a role is based on the observation that chronic administration of many of these cytokines, either alone or in combination, can reproduce the myriad of host responses seen in experimental and human cancer cachexia. Elevated plasma levels of tumor necrosis factor-α, interleukin-1, and inteferon-γ have rarely been detected in patients or experimental animals with cancer, although interleukin-6 levels appear to correlate with tumor progression in animal models. The strongest evidence for a causal role for cytokines has come from rodent studies in which tumor-bearing animals have been passively immunized with antibodies directed against individual cytokines. Several groups have shown modest but significant improvements in food intake and lean tissue retention with antibodies directed against tumor necrosis factor-α, interleukin-1, interleukin-6, and interferon-γ. However, there has been no consistent finding that one cytokine is universally involved in cancer cachexia in histologically distinct tumor models. One ominous finding in several tumor models has been that the endogenous production of cytokines appears to support tumor growth. Such findings raise the intriguing possibility that these cytokines, although contributors to tissue wasting and anorexia, may also serve the tumor as either direct or indirect cell growth factors. We conclude, however, that because of redundancy in the cytokine network and differential cytokine production in histologically distinct tumors, efforts to block the development of cancer cachexia with anticytokine therapies will require the inhibition of several proinflammatory cytokines simultaneously. (Journal of Parenteral and Enteral Nutrition 16:43S-49S, 1992)Keywords
This publication has 41 references indexed in Scilit:
- Anti-interferon-γ antibody treatment, growth of Lewis lung tumours in mice and tumour-associated cachexiaEuropean Journal of Cancer and Clinical Oncology, 1991
- Tumor necrosis factor‐α and interleukin‐1α production in cachectic, tumor‐bearing miceInternational Journal of Cancer, 1990
- Tumor cytotoxicity and interleukin 1 production of blood monocytes of lung cancer patientsCancer Immunology, Immunotherapy, 1990
- Appearance of hybridoma growth factor/interleukin-6 in the serum of mice bearing a methylcholanthrene-induced sarcomaBiochemical and Biophysical Research Communications, 1988
- MONOCYTE TNF PRODUCTION IN GASTROINTESTINAL CANCERThe Lancet, 1988
- Is Circulating Tumor Necrosis Factor Bioactive?New England Journal of Medicine, 1988
- Monocytic production and plasma bioactivities of interleukin‐1 and tumour necrosis factor in human cancerEuropean Journal of Clinical Investigation, 1988
- Tumor Necrosis Factor Not Detectable in Patients With Clinical Cancer CachexiaJNCI Journal of the National Cancer Institute, 1988
- Changes in energy expenditure and fat metabolism in rats infused with interleukin‐1European Journal of Clinical Investigation, 1987
- Tumors secreting human TNF/cachectin induce cachexia in miceCell, 1987